#United States #New York #Class Action #Levi & Korsinsky #Unicycive Therapeutics

Important Notice for Unicycive Therapeutics Investors

Levi & Korsinsky, LLP, a prominent law firm, has issued an urgent reminder to investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) regarding a significant class action lawsuit. Shareholders are alerted that the deadline to request to be designated as lead plaintiff in this litigation is set for October 14, 2025. This action enables concerned investors to recover losses incurred due to alleged securities fraud, impacting those invested between March 29, 2024, and June 27, 2025.

Overview of the Case

The lawsuit alleges that the defendants provided false information and failed to disclose crucial information regarding Unicycive’s compliance with FDA manufacturing requirements. For instance, it was claimed that the company’s readiness to meet these standards was exaggerated, along with the regulatory viability of its oxylanthanum carbonate drug application. This misleading information potentially deceived investors about the company's true operational status, resulting in significant financial losses for many.

What Investors Need to Know

If you are a shareholder who has suffered financial harm from Unicycive Therapeutics during the specified timeframe, Levi & Korsinsky encourages you to consider your legal options. The firm has laid out a few steps for affected investors:
1. Contact Information: You can reach out to attorney Joseph E. Levi via email at [email protected] or by calling (212) 363-7500 for guidance.
2. Filing a Lead Plaintiff Request: To be in the running for recovery, you must file a lead plaintiff application by October 14, 2025. However, participation in the lawsuit and any potential recovery does not require lead plaintiff status.
3. No Cost Involved: Participation in this lawsuit comes without any fees or out-of-pocket expenses for class members. This provides an opportunity for those affected to recover their damages without financial risk.

The Reputation of Levi & Korsinsky

With over two decades of experience, Levi & Korsinsky has become a trusted name in securities litigation. The firm has successfully recovered hundreds of millions of dollars for shareholders, solidifying its reputation as a top firm in this field. They have a dedicated team of over 70 professionals poised to assist investors in navigating the complexities of securities fraud cases.

Next Steps for Affected Investors

Affected shareholders are encouraged to act promptly, as the window to file a request to be appointed lead plaintiff is closing soon. Keep in mind that being involved in the case could help secure justice and potentially reclaim lost investments. For further details, investors can visit the firm’s website:
Levi & Korsinsky Law

Conclusion

It is crucial for Unicycive Therapeutics shareholders to stay informed about their rights and options available to them amidst this legal action. With the deadline approaching, interested parties should take immediate action to ensure their interests are protected. For more personalized guidance, do not hesitate to contact Levi & Korsinsky directly.